Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals with Buy Rating, Announces Price Target of $10

Benzinga · 05/08 14:08
Maxim Group analyst Jason McCarthy initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announces Price Target of $10.